SCHEMBL6891825

SCHEMBL6891825

Nc1c(Cl)c(N2CCN3C(=O)NC(=O)C3C2)nc2c(-c3cnc4ccccc4c3)cnn12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.37
CREBBP Q92793 2/20 0.37
EGFR P00533 5/20 0.34
FGFR2 P21802 5/20 0.34
PIK3CA P42336 2/20 0.33
TDP2 O95551 1/20 0.33
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
PARP10 Q53GL7 1/20 0.32
PARP11 Q9NR21 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
LCK P06239 3/20 0.31
HCK P08631 2/20 0.31
AKR1C3 P42330 1/20 0.31
AKR1C2 P52895 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
KDR P35968 1/20 0.31
SRC P12931 1/20 0.31
AKT1 P31749 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6893405 0.90 EGFR (0.35) BRD4CREBBPEGFRFGFR2PIK3CA
SCHEMBL6893362 0.88 BRD4 (0.34) BRD4CREBBPEGFRFGFR2PIK3CA
SCHEMBL6894421 0.88 BRD4 (0.40) BRD4CREBBPEGFRFGFR2PIK3CA
SCHEMBL7885236 0.88 PIK3CA (0.36) BRD4CREBBPEGFRFGFR2PIK3CA
SCHEMBL2680938 0.86 PIK3CA (0.35) BRD4CREBBPEGFRFGFR2PIK3CA
SCHEMBL6894420 0.84 PIK3CA (0.36) BRD4CREBBPEGFRFGFR2PIK3CA
SCHEMBL6896831 0.83 BRD4 (0.35) BRD4CREBBPEGFRFGFR2PIK3CA
SCHEMBL584020 0.80 CHRNB2 (0.43) NPC1RAB9AMEN1KMT2ALCK
SCHEMBL6894910 0.79 CHEK1 (0.40) BRD4CREBBPEGFRFGFR2PIK3CA
SCHEMBL7886236 0.79 BRD4 (0.34) BRD4CREBBPEGFRFGFR2PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 BRD4 1555/4885CREBBP 1744/4885EGFR 4536/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR BRD4 1117/4885CREBBP 612/4885EGFR 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.